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Abstract 
 
Background: The Myopia Outcome Study of Atropine in Children (MOSAIC) aims to 
explore the efficacy, safety, acceptability and mechanisms of action of 0.01% 
unpreserved atropine for myopia control in a European population. 
Methods: MOSAIC is an investigator-led, double-masked, placebo-controlled, 
randomised clinical trial (RCT) investigating the efficacy, safety and mechanisms of 
action of 0.01% atropine for managing progression of myopia. During Phase 1 of the 
trial, 250 children aged 6-16 years with progressive myopia instil eye drops once nightly 
in both eyes from randomisation to month 24. No treatment is given during Phase 2 
from month 24 to 36 (washout period) for those participants initially randomised to the 
intervention arm (n=167), during which any potential rebound effects on cessation of 
treatment will be monitored. All participants initially assigned to the placebo (n=83) 
crossover to the intervention arm of the study for Phase 2, and from month 24 to 36, 
instil 0.01% atropine eye drops in both eyes once nightly. Further treatment and 
monitoring beyond 36 months is planned (Phase 3) and will be designed dependent on 
the outcomes of Phase 1.  
Results: The primary outcome measure is cycloplegic spherical equivalent refractive 
error progression at 24 months. Secondary outcome measures include axial length 
change as well as the rebound, safety and acceptability profile of 0.01% atropine. 
Additional analyses will include the mechanisms of action of 0.01% atropine for 
myopia control.  
Conclusions: The generalisability of results from previous clinical trials investigating 
atropine for myopia control is limited by the predominantly Asian ethnicity of previous 
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study populations. MOSAIC is the first RCT to explore the efficacy, safety and 
mechanisms of action of unpreserved 0.01% atropine in a predominantly White 
population.  
Trial registration: ISRCTN: ISRCTN36732601 (04/10/2017), EudraCTdatabase 2016-
003340-37 (03/07/2018). 
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Introduction 
 
Myopia is expected to affect 2.5 billion people by 2020 and close to 5 billion by 2050.1,2 
Developed countries in East and Southeast Asia have the highest prevalence of 
adolescent myopia, with over 90% of 18 year olds in Singapore and 72%  in China 
affected.3 There is also evidence that myopia prevalence is increasing in Europe, with 
myopia affecting almost 50% of 25 to 29 year olds, and the proportion of myopic 
children more than doubling in the UK over the last 50 years.4–6 Likewise, in the past 30 
years, myopia prevalence has almost doubled in the United States affecting almost 50% 
of school-leavers.7 Standard clinical care of myopia progression, however, only 
addresses the optical impact of this condition, rather than treating its underlying 
biological basis.8  
 
Epidemiological studies indicate that myopia is second only to age as a risk factor for 
several eye diseases including glaucoma, cataract and retinal detachment,9 and is the 
primary risk factor in myopic maculopathy.10 Myopic maculopathy is a leading cause of 
blindness throughout Asia11 and has been consistently shown as a major cause of 
blindness among the working age population across Europe.12–16  Myopic maculopathy 
is a leading cause of blindness, there is no available treatment, no proven aetiological 
basis and relatively little research funding.  
 
Research in several Asian countries including Singapore, China, Korea and Taiwan has 
demonstrated that atropine eye drops significantly slow myopia progression.17–22 A 
recent network meta-analysis suggests that atropine, at various doses, is the most 
effective therapy for controlling refractive error and axial eye growth progression.23 As 
the risk of complications increases monotonically with the degree of myopia,9 slower 
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progression has the potential to substantially reduce the prevalence of myopia-related 
vision impairment and the associated quality-of-life and socio-economic impacts.  
Administered as an eye drop, atropine blocks the muscarinic receptors in the pupillary 
sphincter musculature, causing pupillary dilatation (mydriasis) which can induce 
symptoms of photophobia. Atropine also reduces or paralyses contraction of the ciliary 
muscle resulting in blurred proximal vision due to loss of accommodation (cycloplegia) 
at its normal 0.5% or 1% clinical dose. The severity and persistence of these atropine 
effects are dose-dependent,18 hence lower doses would be expected to have lesser 
mydriatic and cycloplegic effect. The principal justification for using 0.01% atropine for 
myopia control comes as a serendipitous finding from the Atropine Treatment Of 
Myopia 2 (ATOM2) study.18 Some of the key findings of ATOM2 included that 0.01% 
atropine achieved excellent control of refractive error progression during the initial 
treatment phase,18 and ultimately demonstrated the best balance of clinical efficacy and 
side-effect (cycloplegia and mydriasis related) profile over the entire five-year study 
duration.24   
There are a number of unresolved issues, however, regarding the use of atropine as a 
myopia control measure. Firstly, most of the atropine studies have been conducted in 
Asia, thus the results of which cannot be simply extrapolated to other populations, 
particularly given that atropine exhibits a high affinity for melanin.25 Although 0.01% 
atropine appears to be well tolerated in a Caucasian population exhibiting light irides,26 
the longer-term safety, acceptability and efficacy of atropine in a Caucasian cohort has 
yet to be defined, indicating the need for suitably designed clinical trials of low-dose 
atropine including other ethnicities. Secondly, the ATOM2 study was not placebo-
controlled, while the ongoing Low-Concentration Atropine for Myopia Progression 
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(LAMP) study was only placebo-controlled for the first year.27  
The suggestion that 0.01% atropine is effective in slowing refractive changes in myopia 
progression has led many hospital ophthalmology departments, particularly in Asia, to 
switch from using higher doses to using 0.01% atropine. There is also increasing uptake 
of low dose atropine in private ophthalmology and optometry practice in many parts of 
the world.28 However, an apparent discordance in the two-year ATOM2 treatment 
outcomes is a concern. While 0.01% atropine apparently slowed refractive error 
progression, the rate of axial elongation in this treatment arm during the initial two-year 
treatment phase was marginally faster than that observed in the historical controls of the 
original ATOM1 placebo control group.29 The year one findings from the LAMP study 
also suggest a dose response effect in relation to the impact of atropine on axial growth, 
but the lack of placebo control in future years of this study eliminates the possibility of 
exploring this issue over a longer treatment time-course.27 The inconsistency between 
refractive and axial growth outcomes is an issue that can only be addressed by a 
placebo-controlled trial of sufficient duration to definitively address the use of 0.01% 
atropine for myopia control. Other unresolved questions include the site and mode of 
action, the optimal concentration and long-term safety of low dose atropine. Most of the 
available research has primarily focussed on efficacy of the drug.30 Therefore 
investigations to assess the effect of atropine on biometric characteristics such as 
choroidal thickness,31 retinal thickness,31 crystalline lens thickness,32,33 anterior chamber 
depth,32,33 optic disc parameters,34 corneal curvature,33 and axial length,23 should also be 
prioritised in order to advance our knowledge in relation to the mechanisms involved in 
the regulation of axial elongation.  
Past clinical trials investigating atropine as a myopia control intervention have used 
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preserved atropine formulations.17,18,23 Although it is possible that the preservative 
component of the drop may enhance penetration of the drug into the anterior 
chamber,35,36 chronic application of eye drops containing preservatives can induce 
significant cytological and histological impairment in ocular tissues,37–39 potentially 
leading to toxic adverse effects and non-tolerance to the eye drop.40 Such potential for 
chronic damage is not ideal for a drug that may be required for use over an extended 
period of time in a paediatric population. Evaluation of the safety and efficacy of an 
unpreserved formulation is an important feature of this trial. 
The Myopia Outcome Study of Atropine In Children (MOSAIC) has been designed to 
address some of these important research questions. The overarching goal of the 
MOSAIC trial is to explore the efficacy, safety, acceptability and mechanisms of action 
of 0.01% atropine for myopia control in European children. Trial funding was awarded 
through the Medical Research Charities Group (MRCG) and funded by the Health 
Research Board (HRB) and Fighting Blindness, a non-profit organisation, under the 
MRCG-HRB Joint Funding Scheme [Grant Number: MRCG 2016-13]. The design and 
methodology of the MOSAIC trial is outlined herein. 
 
Methods 
 
Management, design and registration 
The management team and relevant structures established to oversee the implementation 
of MOSAIC, including the data safety monitoring committee (DSMC), trial steering 
committee (TSC) and scientific advisory committee (SAC), are outlined in Figure 1. 
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Figure 1. MOSAIC support and oversight structures 
 
 
MOSAIC is an investigator-led, double-masked, placebo-controlled, randomised 
clinical trial (RCT) designed to assess the efficacy, safety, acceptability and 
mechanisms of action of 0.01% atropine for controlling myopia in children. The trial 
protocol, developed according to Standard Protocol Items Recommendations for 
Interventional Trials (SPIRIT) guidelines, is registered on the current controlled trials 
register with the International Standard Randomised Controlled Trials Number 
36732601 (ISRCTN36732601) on 4 October 2017 and also on the EudraCTdatabase 
(2016-003340-37) on the 3 July 2018. The trial is a single centre study conducted at the 
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The progress of participants through the phases of MOSAIC are shown in Figure 2 in 
the consolidated standards of reporting trials (CONSORT) diagram.41 SPIRIT and 
CONSORT reporting checklists for MOSAIC are deposited in TU Dublin’s ARROW 
repository (see Reporting guidelines42,43).   
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Patient and public involvement 
Baseline Examination &
Eligibility Assessment
Phase 2
Crossover
Phase 3
Retreatment
Phase 1
Treatment
Crossover to allocated intervention (0.01% atropine) 
Examination at 30 and 36 months
12 month washout period (no treatment given) 
Examination at 30 and 36 months
Excluded
Not eligible to participant
Declined to participate 
Other reasons 
Randomised n=250
Allocated to intervention (n=167)
Received allocated intervention (0.01% atropine)
Allocated to intervention (n=83)
Received allocated intervention (placebo)  
24 month follow up. 
Examination at baseline, 6, 12, 18 and 24 months  
24 month follow up. 
Examination at baseline, 6, 12, 18 and 24 months  
Continuous monitoring, washout and 
retreatment with 0.01% or 0.02% atropine 
dependent on myopia progression status
Figure 2. Flow of participants through the MOSAIC clinical trial. 
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The MOSAIC protocol and clinical trial documentation were designed to maximise the 
benefits of patient and public involvement (PPI) throughout the clinical trial.44 All 
MOSAIC clinical trial documentation, including consent/assent forms, participant 
information leaflets and parental questionnaires, were submitted through Fighting 
Blindness for PPI review. The collated feedback was analysed, and the relevant clinical 
trial documentation was amended to reflect PPI recommendations. 
 
Research question 
To address whether it is clinically justifiable and feasible to offer atropine eye drops to 
limit the progression of myopia in a European population. This will be achieved by 
determining the efficacy, safety and acceptability of 0.01% atropine treatment.  
 
Primary outcome measure 
Change in spherical equivalent refraction at 24 months measured by cycloplegic auto-
refraction. 
 
Secondary outcome measures  
1. Efficacy 
• Change in ocular axial length at 24 months measured by optical low-coherence 
interferometry. 
• Change in spherical equivalent refraction at 12 months measured by cycloplegic 
auto-refraction. 
• Change in ocular axial length at 12 months measured by optical low-coherence 
interferometry. 
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• Percentage of participants who progress <0.25D (dioptre), 0.25D£0.75D and 
>0.75D in 24 months. 
• Rebound acceleration in myopic refractive error after cessation of atropine 
treatment, measured as change in spherical equivalent refraction and axial length 
between 24 and 36 months. 
 
2. Mechanisms of action	
• Effects on off-axis refraction measured by cycloplegic auto-refraction at 24 
months. 
• Effects on ocular growth (including retinal vascular morphology, ocular 
biometry, corneal topography, anterior chamber, lens thickness, retinal nerve 
fibre layer and choroidal thickness) at 24 months. 
 
3. Safety and acceptability 
• Changes in visual performance (distance and near visual acuity (VA), 
stereoacuity) at 24 months. 
• Effects on ocular physiological response (amplitude of accommodation, 
accommodative facility, lag of accommodation, near point of convergence, pupil 
size and pupil reactivity) at 24 months. 
• Quality of life impact associated with atropine use at 24 months. 
• Frequency of adverse events recorded on study-specific report forms. 
• Participant dropout rate during the trial. 
• Compliance with trial medication.  
 
Drug manufacture and supply 
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Unpreserved atropine 0.01% is supplied by the pharmaceutical company Nevakar 
(Nevakar, Inc. 1019 US Highway 202-206, Building K, NJ Center of Excellence, 
Bridgewater, NJ 08807, USA) for the duration of the clinical trial. Nevakar’s contracted 
manufacturer, Excelvision, has a current EU GMPD Certificate and is authorised to 
manufacture atropine 0.01% and placebo eye drops on behalf of Nevakar, in accordance 
with the requirements of the EU Guide to Good Manufacturing Practice. The eye drops 
are manufactured at a site authorised for manufacture of aseptically prepared small 
volume liquids. Investigational product labelling, packaging and QP release to the trial 
centre is provided by Xerimis. 
 
Trial intervention  
The intervention for the trial is 0.01% w/v atropine eyedrops, an anti-cholinergic agent 
selective for muscarinic receptors. Unpreserved 0.01% w/v atropine solution is supplied 
to trial participants as single dose ampoules for daily use. The placebo solution, 
identical to the atropine eye drop formulation without the active ingredient (atropine), is 
also supplied to trial participants as single dose ampoules for daily use. 
During Phase 1 of MOSAIC, participants instil eye drops (atropine or placebo, per their 
randomisation status) once nightly into both eyes from the baseline visit to month 24. 
This is followed by Phase 2 where no treatment is given from month 24-to-36 (washout 
period) for those participants initially randomised to atropine. Participants are 
monitored in this washout period to examine any potential rebound effects on 
termination of treatment. All participants initially assigned to the placebo group then 
crossover to the intervention arm of the study, and for the period from month 24 to 36, 
instil 0.01% atropine eye drops once nightly. An additional monitoring and re-treatment 
phase is planned (Phase 3), the design of which will be informed by (i) the outcomes of 
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Phase 1, (ii) consultation with our TSC and SAC, (iii) regulatory approval and (iv) 
funding availability. To ensure the study population is representative of the Irish 
population, recruitment is capped by ethnic background in accordance with ethnic 
classifications in the 2016 Irish Census.45  
 
 
Randomisation  
The Mater Misericordiae University Hospital (MMUH) Clinical Research Centre (CRC) 
will carry out the stratified randomisation procedure. Participants are allocated to one of 
the two intervention groups according to a 2:1 treatment to control ratio to maximise 
recruitment success. Allocation is carried out using block randomisation and stratified 
according to baseline refractive error (<-3D or ≥ -3D). A randomisation list for each 
strata will be prepared by an independent statistician and will be stored within the CRC.  
 
A key advantage of block randomisation is that treatment groups tend to be uniformly 
distributed by key outcome-related characteristics and the 2:1 assignment of participants 
remains similar at all times,46 even if the full quota of participants are not recruited into 
the clinical trial. Participants are randomised to a study number unrelated to treatment 
assignment. Once officially enrolled on the trial, participants receive a unique study 
identification number at the baseline visit that is pre-randomised to one of the 
intervention arms.  
 
Masking  
Study treatment assignment is double masked during the first 24 months. Atropine and 
placebo eye drops are packaged identically before delivery of the investigational 
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product to the trial centre, so that the investigator and participants are unable to identify 
the contents. Labels on the box containing the ampoules have a batch number (that does 
not indicate to the investigator whether it is atropine or the placebo), study reference 
number, participant ID, trial sponsor’s name and contact number, investigator name, site 
address, expiration date of the eye drop, storage instructions, and a statement informing 
the participant that the drop is for clinical trial use only and is not to be ingested.  
 
No interim analyses are planned. The randomisation code is only broken after all 
participants have completed the 24-month visit and all data have been subjected to a 
“Blind Review”. This pre-analysis review, masked to treatment, covers, for example, 
decisions concerning the exclusion of participants or data from the analysis sets, the 
checking of possible transformations and definitions of outliers, the addition to the 
model of important covariates identified in other recent research, and other factors that 
might be of relevant to the data analysis. Decisions made at this time are described in a 
report and distinguished from those made after the study statistician has had access to 
the treatment codes when final decisions can be adequately taken, as masked decisions 
generally introduce less potential for bias. Only the DSMC has access to the 
randomisation list to determine allocation to atropine or placebo within the appropriate 
strata, as well as to facilitate interim trial safety analyses. To reduce performance and 
ascertainment bias after randomisation, measures are taken as far as is practical to 
maintain investigator masking.  
 
Storage and disposal of study treatment 
The trial intervention drug and placebo eye drops are securely stored at the clinical trial 
site (CERI). Only the study investigators and the senior research assistant have access to 
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the eye drops. Study medication, monitored constantly with Bluetooth temperature 
sensors, is stored at room temperature of 20°C to 25° C, with minimal excursions 
permitted. A room temperature log is maintained at the study site. Subjects and their 
parent/guardian are also instructed to store the eyedrops at room temperature with no 
exposure to extreme temperatures (such as refrigeration).  
 
Parents are provided with a study treatment kit set at each visit. Each kit contains a 6-
month supply of eye drops consisting of 200-unit dose ampoules. Each 6-month 
treatment kit consists of two 3-month boxes and each box consists of 20 aluminium foil 
pouches. Each foil pouch consists of 5-unit dose ampoules. Parents are instructed to 
open one ampoule per day and administer the eye drop into both eyes of the participant 
once nightly. After instillation of the eye drop, the open ampoule and the remaining 
contents should be placed in the provided receptacle that is returned to the study centre 
for accounting and proper disposal. All returned ampoules are deposited in 
appropriately labelled hazardous waste containers and disposed of in keeping with 
chemical waste management policies and procedures. Parents are provided with an 
information sheet on correct eyedrop use. This includes an instruction to start a new box 
each month irrespective of how many ampoules remain in the previous box. A contact 
phone number is also provided in the participant’s study information pack as well as the 
product label, in case the parent has any queries.  
 
Compliance 
The study medication is provided to participants at each study visit during their 
treatment period. Parents sign to confirm they have received the eye drops once 
dispensed and are asked to bring trial boxes containing their remaining unused 
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ampoules on all visits after the baseline visit. Parents are provided with a list of 
suggestions to encourage adherence, and are asked to create a nightly calendar 
reminder, as well as a calendar log of date and time of eye drop instillation on their 
phone. Regular phone and text message contact is maintained with parents throughout 
the study duration. Participants and their parents are questioned regarding adherence at 
each visit and are constantly reminded about the importance of adhering to the treatment 
protocol.  
 
Participants are encouraged to attend all study visits. Follow up visits are scheduled at 6, 
12, 18, 24, 30 and 36 months after the baseline randomisation visit, +/- 2 weeks. Thus, 
clinic visits are scheduled from up to 2 weeks before the check-up date is due.  If the 
participant does not attend the visit, a new visit is rescheduled within 4 weeks in the 
first 12 months of the trial and within 6 weeks thereafter. Participants are informed that 
they may be removed from the trial if they fail to attend within the defined time period. 
If a participant is dropped from the trial for this, or any other reason, arrangements are 
made for collecting used and unused ampoules.  
The study is to be conducted using an intention-to-treat basis. The level of compliance 
with eyedrop use is quantified by questionnaire (self-report), the eyedrop use calendar 
log and quantification of returned ampoules. There is no minimum eyedrop insertion 
compliance criterion that would cause removal from the trial, but compliance is 
controlled for in statistical analyses and used as a measure of acceptability of the 
treatment in our secondary objectives.  
Any suspected non-compliance or improper eye drop use results in encouragement to 
parents and children as well as offering an electronic daily reminder system for families 
who have not instilled the drop as instructed. Evidence of over use is also discussed 
	 20	
with participants and they are re-instructed on proper use and compliance with the once-
nightly protocol. 
 
Sample size calculation 
Based on available atropine trial data from Singapore,17 along with Pirenzepine trials 
data from the USA,47  myopia progression in the atropine treatment group is postulated 
to be -0.25D per annum, with a standard deviation of ±0.3D at two time points (12 
months and 24 months). Power analysis of these data resulted in a projected effect 
difference of 50% between the intervention versus the placebo control group on myopia 
progression rate. The primary outcome for this study is the progression of myopia over 
the 2-year trial duration sampled every 6 months. The analyses of progression of 
myopia will be a 2x5 repeated measures mixed analysis of variance (ANOVA) with the 
factors of group (placebo and intervention) and time (0 months, 6 months, 12months, 18 
months, 24 months). Conducting a power analysis for the repeated measures (RM) 
ANOVA, anticipating a conservative effect size of 0.3, an alpha of 5%, a power of 95%, 
with two groups, five repeated measurements and a correlation among the repeated 
measures of 0.9 resulted in a sample size of 136 with a critical F value of 3.91179. 
Allowing for a high potential attrition rate (based on the fact that no trial has been 
conducted to completion in a European population, in whom the acceptability and 
motivation for long term use remain unknown), a total of 250 children will be recruited. 
Of these, 167 children will be randomised to the intervention group and 83 to the 
placebo group.  
The study is powered for the primary outcome. However, for secondary measures or 
subgroup analyses, the MOSAIC team will lead a planned meta-analysis of these data 
combined with data from ongoing trials in the UK (CHAMP-UK: ISRCTN99883695) 
	 21	
and Australia (ATOM-Australia: ACTRN12617000598381). Such a meta-analysis will 
provide additional statistical power for subgroup and secondary analyses and allow a 
more definitive exploration of the mechanistic components of atropine’s influence on 
myopia progression. 
 
Eligibility criteria 
Only participants between the ages of six to 16 years inclusive are eligible to participate 
in the trial. Additional inclusion criteria comprise:  
1. Refractive criteria 
• A spherical equivalent refractive error of -1.0D or worse 
• Evidence of myopic progression over the preceding year 
• Astigmatism less than -2.50D and the least myopic meridian must be more 
myopic or equal to -0.50D 
• Corrected visual acuity of 0.2 logMAR (logarithm of the minimum angle of 
resolution) or better in both eyes 
• Normal binocular vision, no history of amblyopia or strabismus 
• No previous pharmaceutical or optical myopia control interventions 
 
2. Health criteria 
• Normal intraocular pressure (IOP) (<= 21mmHg) 
• Normal ocular health, with no history of glaucoma or any other ocular diseases 
or ocular surgery 
• No significant or severe corneal damage or scarring 
• Good general health with no history of myasthenia gravis or any cardiac, 
respiratory, kidney or urinary disease or dysfunction 
	 22	
• No known allergy to atropine, cyclopentolate hydrochloride and/or 
proxymetacaine hydrochloride 
• A negative pregnancy test for females with childbearing potential 
 
3. Capacity criteria  
• Willingness to commit to the duration of the clinical trial and to accept the 
possibility of randomisation to the placebo arm. 
• Ability of the participant (or parent/guardian) to provide written informed 
consent.  
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Study recruitment 
Participants are recruited into this trial through a variety of channels, each of which 
were established prior to commencement of the pre-trial phase and are continued 
throughout the study until recruitment is complete. These avenues included: 
 
1. National and local ophthalmic professional engagement: information leaflets and 
flyers (containing clinical trial information including trial eligibility criteria) 
were sent to optometrists in the community advising them of the study and to 
relate this information to potential participants and their parents/guardians.48 
Information packs (containing information leaflets for optometrists and for 
parent, as well as flyers) were also distributed at various ophthalmic continuing 
professional development and networking events. Flyers are now displayed in 
clinical practices and in the National Optometry Centre, Dublin, Ireland.48  
2. Professional associations such as the Association of Optometrists Ireland and 
Irish College of Ophthalmologists were approached to seek and facilitate 
involvement of their members in providing information on the trial to potential 
participants in hospital, community practice and public health settings. 
3. TU Dublin collaborations: The Access and Civic Engagement Office in TU 
Dublin was utilised to promote engagement with local schools, while additional 
school contacts were used to engage schools outside Dublin. 
4. Organised advertising campaign: a parallel media campaign promoted awareness 
of the trial. National and local media were informed of the trial. Radio, 
newspaper and online advertisements were disseminated. 
(http://www.ceri.ie/assets/information-leaflet_myopia_ceri.pdf, 
https://www.rte.ie/brainstorm/2018/0904/991568-what-tech-is-doing-to-your-
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eyesight/, https://www.irishtimes.com/life-and-style/health-family/lifestyle-
linked-to-huge-increase-in-short-sightedness-1.3397726,) 
5. A dedicated project website (http://www.ceri.ie/myopia-control.html) and social 
media presence (https://www.facebook.com/pg/ceri.ie/posts,  
 https://twitter.com/ceri_dit?lang=en, http://hotsta.org/ceri.ie) maintained by the 
project senior research assistant provided information on the study and promoted 
the study.  
 
Informed consent 
In compliance with the National Consent Policy of Ireland (2013 -16 Document 
reference QPSD-D-026-1), parental consent and child assent (dependent on child age 
and maturity) is required before any trial-related procedures are undertaken. Study 
investigators ensure that parents and children understand the trial completely including 
all information on the participant information leaflet. All study information is available 
in a child-accessible format. Participants are informed if they are eligible at the baseline 
visit. All participants are given the opportunity to ask any questions about the study 
prior to parental consent and child assent being obtained and may withdraw consent at 
any time. Participant consent is collected in hardcopy and a copy is provided to the 
participants. 
  
Study visits 
At the baseline visit, each participants’ eligibility is confirmed, the ability of the parent 
to instil and participants’ ability to tolerate the instillation of an artificial tear eye drop is 
assessed. The participant or parent/guardian is given the allotted atropine or placebo eye 
drops to take home and instil one drop every night into both eyes for the trial duration. 
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After the baseline visit, study visits are conducted at 6, 12, 18, 24, 30 and 36 months. 
Each visit takes approximately 90 minutes. Table 1 summarises the clinical procedures 
conducted at each visit.  
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Procedures 
Phase 1 Phase 2 Phase 3 
Visit 1 
Baseline 
Visit 2 
6 months 
Visit 3 
12 months 
 
Visit 4 
18 months 
 
Visit 5 
24 months 
Finish 
tx/crossove
r 
Visit 6 
6 months 
into  
crossover & 
washout 
Visit 7 
12 months 
into  
crossover & 
washout 
Visit 8 
6 months  
crossover 
washout, 
monitoring/ 
re-tx 
Visit 9 
12 months  
crossover 
washout, 
monitoring/ 
re-tx 
Inclusion/Exclusion 
Criteria 
✔ ✔ ✔ ✔ ✔     
Informed Consent ✔         
Medical History ✔         
Review of Medical 
History 
 ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
Heart Rate ✔ ✔ ✔ ✔ ✔ ✔* ✔*   
Height ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
Weight ✔         
Pregnancy Test ✔         
Parental Autorefractor ✔         
Visual Acuity ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
Accommodative Lag/ 
Facility/Amplitude 
✔    ✔  ✔  ✔ 
Near Point of 
Convergence 
✔    ✔  ✔  ✔ 
Near VA ✔    ✔  ✔  ✔ 
IR Pupillometry ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
Tonometry ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
Table 1. MOSAIC clinical procedures during Phase 1, 2 and 3 of the trial.  
Abbreviations: Tx, Treatment; *, Only for those participants who crossover to atropine treatment; **, Only for those participants 
undergoing re-treatment 
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Objective Refraction ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
Off-Axis Refraction ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
Fundus Image ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
Corneal Topography ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
Slit lamp Assessment ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
Ocular Biometry ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
Optical Coherence 
Tomography 
✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
Confocal Scanning Laser 
Ophthalmoscopy 
✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
Adverse event monitoring  ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
Compliance check  ✔ ✔ ✔ ✔ ✔* ✔*   
Questionnaires  ✔ ✔ ✔ ✔ ✔    
Dispensing of atropine or 
placebo 
✔ ✔ ✔ ✔ ✔ ✔ ✔** ✔**  
 
 
Description of study assessments 
Demographics and inclusion/exclusion Criteria  
At the initial screening visit all parents are required to complete a demographic and 
health questionnaire on behalf of their child. Demographic information includes age, 
sex and race. Iris colour is documented.49 Medical and ocular history, including the 
participant’s GP and optometrist name and address, is also collected. To participate in 
the trial, participants must satisfy all the inclusion and exclusion criteria outlined. 
 
Medical and surgical history 
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A detailed medical and surgical case history is undertaken in order to ensure that all trial 
participants are in good general and ocular health and comply with the study inclusion 
and exclusion criteria, including any history of ocular surgery, amblyopia and patching 
as well as detailing any allergies to atropine sulphate, hydroxypropyl methylcellulose, 
proxymetacaine hydrochloride or cyclopentolate hydrochloride.   
Heart Rate is measured at baseline and every 6 months thereafter until the final study 
visit. Heart rate is measured with a heart rate monitor after approximately 3 minutes of 
rest in the seated position. The participant is excluded if heart rate is persistently (for 
more than 10 minutes) > 120 beats per minute at any study visit. 
Females of childbearing potential are required to provide confirmation of last menstrual 
period and a negative pregnancy test. Sexually active participants are advised to use an 
acceptable, effective form of contraception until cessation of treatment. 
 
Pre-cycloplegia measures 
Visual acuity 
Participants’ corrected visual acuity is measured using a randomised letterset of the 
MultiQuity (MiQ 720) computerised logMAR chart.  
 
Accommodation and convergence  
Amplitude of accommodation (AoA) and near point of convergence (NPC) are 
measured non-invasively with a RAF (Royal Air Force) rule using the subjective push-
up technique. Measurements are taken both monocularly and binocularly for AoA and 
binocularly for NPC. Lag of accommodation to a 40cm (2.5D) target is measured using 
the Grand Seiko WAM 5500 open field autorefractor. Accommodative facility is 
measured using ±2.00D flippers at near. 
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Near VA  
Near visual acuity is documented to monitor any changes in visual performance. Near 
visual acuity is determined as the smallest character size that can be read at 25cms.  
 
Infrared pupillometry 
The Topcon ALADDIN optical biometer is used to measure scotopic and photopic 
pupil size and pupil reactivity for each participant at each visit. Atropine causes 
pupillary dilation, particularly at higher concentrations used in previous trials. This 
measure is taken pre- and post-cycloplegia and is used to determine the physiological 
impact of 0.01% atropine on pupillary function as well as to confirm cycloplegia. 
 
Tonometry 
An Icare tonometer is used to calculate the intraocular pressure in both eyes at each study 
visit pre- and post-cycloplegia. This measure is taken at all visits as a safety precaution for 
participants.  
 
Post cycloplegia measures 
Objective refraction 
Refractive error and peripheral refractive error are measured by cycloplegic auto-
refraction at the baseline visit using the Grand Seiko WAM 5500 open field 
autorefractor. Change in spherical equivalent refraction and peripheral refraction (30° 
nasal and temporal) are measured by cycloplegic auto-refraction at all subsequent visits. 
One drop of 1% cyclopentolate is instilled 30 minutes prior to auto-refraction. 
Cycloplegia is confirmed using measures of pupil size, pupil dynamics and near visual 
	 30	
acuity. If both pupils are not dilating and amplitude of accommodation is not reducing 
after 15 minutes, a second drop of 1% cyclopentolate is instilled. 
 
 
Choroidal thickness 
Swept source optical coherence tomography (OCT) provides a significant improvement 
over conventional OCT, in particular, there is better penetration of the deeper layers of 
the eye including the choroid. The	7×7	macula	scan	on	the	Topcon DRI OCT Triton, 
facilitates automated choroidal thickness mapping at each study visit.  
 
Retinal vasculature 
The	7×7	macula	and	angiography	scans	on the Topcon DRI OCT Triton allows 
imaging of the central and peripheral retina for detailed analysis of change in retinal 
vessels in relation to ocular growth and also to examine and monitor retinal health 
throughout and after the clinical trial. 	
 
Slit lamp assessment 
The slit lamp is used to perform a complete examination of the external eye as a safety 
precaution throughout the trial in case of sign of allergy or external abnormality. This 
includes examination of the cornea, conjunctiva, iris, pupil, lids and adnexa, relative to the 
Brien Holden Vision Institute grading scale where appropiate.50 Results are recorded at 
each visit study visit, including visits during the washout period. As the study medication 
contains phosphates, inclusion in the study requires a healthy cornea with no evidence of 
corneal damage or scarring. Cases of corneal calcification have been reported very rarely 
in association with the use of phosphate-containing eye drops in some patients with 
significantly damaged corneas.51,52 
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Ocular biometry 
The Topcon ALADDIN optical biometer is used to determine the axial length, anterior 
chamber depth, pupil size, keratometry, dynamic pupil measurements, white to white 
and lens thickness at the baseline visit. Changes in dynamic pupil measurements, ocular 
axial length, anterior chamber depth and/or lens thickness are documented by repeat 
measurements at all subsequent visits.  
 
Adverse event assessments 
A detailed adverse events assessment will be conducted at each visit, which includes 
specific evaluation as to the experience of known adverse side effects of topical atropine 
which can include: 
• Reading difficulties: some degree of cycloplegia is anticipated while using 
0.01% atropine.  
• Glare: an increase in pupil size and loss of reactivity is expected while using 
0.01% atropine. 
• Other, less common and rare ophthalmic adverse effects of atropine may 
include conjunctival irritation, follicular conjunctivitis, increased intraocular 
pressure (especially in patients with closed-angle glaucoma), and swelling of 
the eyelids. Participants and parents are provided with information 
describing the clinical signs of the above adverse effects, and given 
appropriate instruction as to appropriate management in each case.  
• Systemic adverse effects: Tachycardia, dryness of the mouth, flushing, 
anhidrosis, heat intolerance or impaired temperature regulation, 
hypersensitivity-associated skin rashes. Participants and parents are provided 
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with information describing the clinical signs of the above adverse effects 
and given instruction as to appropriate management in each case. Heart Rate 
is measured at baseline and every six months thereafter until month 24. 
Heart rate is monitored at month 30 and 36 for those participants who have 
crossed over to atropine treatment. 
The detailed examination carried out at each study visit is used to determine any 
symptomatic or asymptomatic adverse responses to atropine use. A detailed case history 
is also used to determine the presence of adverse events attributable to the therapeutic 
intervention. Occurrence of adverse events are recorded on study-specific adverse report 
forms. The DSMC review all adverse events and safety data on a quarterly basis, or 
more frequently if required by any emerging safety concerns during the study.  
In the unlikely scenario of a serious adverse event, our team includes a paediatric 
ophthalmic surgeon, who will make arrangements for ophthalmic service provision with 
ophthalmology and medical colleagues, as appropriate, to manage ophthalmic adverse 
events/effects as may be required. Non-ophthalmic adverse events are managed through 
appropriate public health channels including the family physician, emergency services, 
accident and emergency unit or other hospital services as may be required. In the event 
an unexpected and serious adverse side-effect is confirmed to be directly attributable to 
the investigational product, the DSMC, TSC and Study Sponsor will liaise with the 
research ethics committee (REC) and Health products Regulatory Authority (HPRA) to 
determine the appropriate course of action.  
 
Questionnaires 
Lifestyle questionnaire 
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At each study visit parents are asked to complete a lifestyle questionnaire to quantify 
lifestyle habits including outdoors exposure, sports participation, near work including 
use of digital technology.48 
 
Quality of Life Impact questionnaire  
The impact or burden of atropine treatment on the child and the family is assessed using 
a validated and atropine specific quality of life questionnaire, adapted from the Parent 
and New Child Amblyopia Treatment Index (ATI) questionnaires used with higher 
atropine concentrations.48,53  
 
Statistical analysis 
Primary efficacy endpoint 
The primary outcome, in line with previous studies,17,54 will be myopia progression 
amongst study groups, primarily the difference in change in myopic refractive error (in 
dioptres) from cycloplegic autorefraction from baseline to month 24. The analysis will 
rely on parametric analysis of variance (ANOVA), to control for the effects of the other 
continuous variables that are not of primary interest. The treatment difference in 
response rate and its 95% confidence interval (CI) will be provided. 
 
Secondary efficacy endpoints 
Univariate analysis will be performed to evaluate the group effect on mean change in 
axial length over the 2-year period. Multivariate regression analyses will be used to 
assess the association between change in axial length and progression of myopia while 
adjusting for treatment effects. The difference in myopic refractive error from 
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cycloplegic autorefraction and axial length between the treatment groups from baseline 
to visit 6 will be analysed using RM ANOVA. 
 
The percentage of participants in each treatment group that progress <0.25D, 
0.25D£0.75D and >0.75D from baseline to visit 6 will be displayed in cross tabulations. 
A post hoc analysis, with Bonferroni correction to account for any type 1 errors, will be 
carried out to determine at what time-point over the 24-month treatment period atropine 
was most effective. 
 
The distribution of scores from the quality of life questionnaire is calculated at each 
visit for all treatment groups. At the 24-month visit the scores for each visit will be 
calculated and analysis of variance (ANOVA) and suitable post hoc testing will be used 
to determine any statistically significant differences between the responses at each visit 
as well as between groups. Safety and tolerability data will be presented in tables of 
descriptive statistics and frequency distribution. RM ANOVA will be used to detect 
changes in anterior chamber depth, crystalline lens thickness, retinal nerve fibre layer 
thickness and choroidal thickness between treatment groups. A statistical significance 
level of p < 0.05 is adopted throughout the analysis. 
 
Adjustment for baseline characteristics will be performed by analysis of covariance 
(ANCOVA). Several comparisons will ensue based on further stratification by a) sex; b) 
age; c) ethnicity; d) baseline refractive error and e) baseline axial length, using data 
pooled from both eyes, assuming the sample size is sufficient. The primary statistical 
analysis will be based on the intention-to-treat principle, but supported by additional 
per-protocol analyses. 
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Trial steering and oversight 
Three committees have been established to provide independent oversight and steer the 
strategic direction of the trial. 
 
Data Safety Monitoring Committee 
A three-member independent DSMC has been established to oversee the safety of trial 
participants. The establishment of the DSMC is justified given the paediatric population 
under investigation and the need to detect any potential harm to participants as early as 
possible, even though the anticipated potential for harm in this trial is very low. Safety 
monitoring will be the major task for the appointed DSMC. All members of the DSMC 
are completely independent of the trial and have no possible financial or other potential 
conflict of interest in the study. The DSMC is composed of a statistician with expertise 
in biomedical research, a paediatric ophthalmologist and an ophthalmologist with 
medical and surgical retina expertise (chairperson). 
 
Trial Steering and Scientific Advisory Committees 
In addition to the DSMC, a TSC and SAC has been appointed to contribute to the 
design and conduct of the trial. The TSC includes individuals with expertise and 
involvement in other atropine trials for myopia control. The SAC includes international 
scientists with expertise in the exploration of efficacy, safety and mechanistic aspects of 
myopia and its control. The trial investigators are represented on the Steering 
Committee by JL and IF. Together the co-PIs maintain responsibility for all study 
design, implementation and oversight across all facets of the study. The TSC hold 
teleconference meetings as required. Meetings address trial strategy, trial protocol and 
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matters arising from the various work packages including staff and other resource 
concerns, data collection and all operational issues as they arise. The scientific and 
clinical members of the steering committee have the responsibility of informing the 
clinical protocol required to effectively and safely implement the trial, including 
determination of patient eligibility, examination protocol, data capture and recording 
protocol, inter-professional communication protocol, and decision review protocol. 
Members of the TSC and SAC are identified in Figure 1. 
 
Regulatory approval 
Regulatory approval for MOSAIC was granted by the Health Products Regulatory 
Authority (HPRA), reference CT0900/622/001. Clinical trials in Ireland are currently 
governed by the European Communities (Clinical Trials on Medicinal Products for 
Human Use) Regulations, 2004, SI No 190 of 2004, transposed into Irish law the 
provisions of Council Directive 2001/20/EC.  
 
Ethics 
Ethical approval for the study was granted by the Research Ethics Committee (REC) at 
the MMUH, Dublin, Ireland (reference 1/478/81), and by the REC at TU Dublin, 
Ireland (reference 16-45). MOSAIC adheres to the tenets of the Declaration of Helsinki 
and follows the full code of ethics with respect to participant recruitment, participant 
testing and General Data Protection Regulations (GDPR, effective May 2018). 
 
As required under the EU Directive on Clinical Trials (European Union - Directive 
2001/20/EC), parental or guardian consent is obtained as required for clinical trials 
involving minors, who are defined in this case as persons under the age of 16 years. 
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MOSAIC is carried out within the framework of Children First: National Guidance for 
the Protection and Welfare of Children (DCYA, 2011). Child assent is also obtained in 
recognition of the importance of the voice of the child in this type of research.55 
 
Dissemination of findings 
Findings and underlying data from MOSAIC will be disseminated at appropriate 
conferences, through scientific publications and published in open access format on the 
TU Dublin ARROW repository. Findings will also be shared online through social 
media channels, blogs, and publications, as well as through print, broadcast and at 
stakeholder events. 
 
Study status 
Recruiting June 2019 to March 2020 
 
Discussion 
 
The study that has principally helped to define the approach and methodology of 
MOSAIC is the ATOM2 study conducted in Singapore.18,56 The ATOM2 study was 
designed to examine the dose:response characteristics of atropine in terms of its positive 
impact on myopia progression, and its negative impact in terms of blurred near vision 
and photophobia, and demonstrated a beneficial effect of 0.01% atropine on myopia 
progression without the adverse effects noted at higher concentrations.18 
Specific design limitations of ATOM2 are addressed in the MOSAIC clinical trial. 
These include a true placebo group, increased participant numbers in the 0.01% 
treatment cohort and removing the potentially confounding effects of varifocal glasses 
that were provided to some of the high-dose groups in the ATOM2 study.  
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MOSAIC will investigate the efficacy, safety and acceptability of 0.01% unpreserved 
atropine solution for the control of myopia in European (predominantly White) children. 
The recruitment strategy is a particular strength of the MOSAIC trial, in that the 
recruitment by ethnic origin will be capped according to the demographics within the 
Irish population according to the most recent census in order to ensure that results are 
truly representative of the Irish population. At the 2016 Irish census, 91.7% of the 
population identified as White.45 This approach will result in the recruitment of an 
equally high proportion of White participants with progressive myopia, a group that has 
yet to be adequately targeted in relation to the safety and efficacy of atropine. Future 
meta-analysis will also permit evaluation of unpreserved 0.01% atropine efficacy and 
safety compared to preserved (CHAMP-UK and WA-ATOM) 0.01% atropine.   
MOSAIC is also designed to ensure that, at least at the time of enrolment, each 
participant exhibits progressive myopia. The principal benefits of this feature include 
that (i) this allows a broader age range of eligible participants which is important in a 
European context where myopia onset is typically later and slower relative to in Asia, 
(ii) it reduces the possibility that the outcomes are confounded by variability in the 
proportion of naturally non-progressive myopes across treatment arms, and (iii) it 
thereby ensures that any differences at the completion of the trial can be attributed to 
atropine treatment.57  
 
MOSAIC will provide novel insights into the mechanisms affecting myopia 
development, as well as the mechanism of action of atropine, which still remains 
unclear.58 The MOSAIC protocol has been made available to other research groups and 
is closely replicated in studies in the UK and Australia, which when pooled for meta-
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analysis will provide increased scope to investigate the mechanism of action for 
atropine’s anti-myopia effect.  
 
Conclusion 
 
Myopia has become a significant global public health problem. The safety and efficacy 
of atropine eye drops in reducing myopia progression has been demonstrated in several 
clinical trials in Asia; however, due to potential inter-ethnic differences, the 
generalisability of such results are limited. The MOSAIC trial can address significant 
evidence gaps that exist in relation to atropine as a myopia control intervention in a 
predominantly White population. MOSAIC’s extensive study design and large sample 
size are major advantages in determining atropine’s efficacy, mechanism of action and 
safety in a Western context. In addition, the planned pooling of data with similar trials 
in future meta-analysis will provide sufficient power for subgroup analysis by age, race, 
initial refraction and atropine formulation. 
 
 
Data availability 
Underlying data 
No data is associated with this article 
 
Extended data 
Extended Data File 1: 
 
Repository: Myopia Outcome Study of Atropine in Children (MOSAIC): Design and 
Methodology. ARROW @ TU Dublin. 2019. doi:https://doi.org/10.21427/xyq9-ck53 
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• MOSAIC	Parent	Information	Leaflet	and	Consent	Form	
• MOSAIC	Child	Information	Leaflet	and	Assent	Form	
• MOSAIC	Baseline	Visit	Eye	Drop	Questionnaire	for	Parents	
• MOSAIC	Follow-up	Visit	Eye	Drop	Questionnaire	for	Parents	
• MOSAIC	Self-Reported	Discomfort	Questionnaire	for	Child	
• MOSAIC	Activity	Diary	
• MOSAIC	Recruitment	Flyer	
• MOSAIC	Study	Information	Pack	
• Myopia	Control	Information	Leaflet	for	Parents	
• Myopia	Control	Information	Pack	for	Optometrists	
 
Reporting guidelines  
ARROW@TU Dublin: CONSORT checklist for ‘Myopia Outcome Study of Atropine 
in Children (MOSAIC): an investigator-led, double-masked, placebo-controlled, 
randomised clinical trial protocol’. https://doi.org/10.21427/3neg-gr7735  
ARROW@TU Dublin: SPIRIT checklist for ‘Myopia Outcome Study of Atropine in 
Children (MOSAIC): an investigator-led, double-masked, placebo-controlled, 
randomised clinical trial protocol’. https://doi.org/10.21427/2dbf-t10336  
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